News
KBRA announces the assignment of preliminary ratings to five classes of VRTX 2025-HQ, a CMBS single-borrower securitization. The collateral for the transaction is a $600 million portion of a $1.0 ...
ZUG, Switzerland and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $481.56, ...
I think that's the case with Vertex. Here are seven reasons why Vertex is a no-brainer stock to buy on the dip.
Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...
Discover key insights from Vertex, Inc.'s Q2 2025 earnings: solid revenue growth, macro challenges, and a focus on e-invoicing opportunities.
1d
Investor's Business Daily on MSNWhy Vertex Pharma Is Feeling The Pain Despite A Second-Quarter BeatVertex stock nose-dived Tuesday after the biotech company said it wouldn't advance its next-generation pain drug into ...
2d
Zacks Investment Research on MSNCompared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key MetricsVertex Pharmaceuticals (VRTX) reported $2.96 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 12.1%. EPS of $4.52 for the same period compares to -$12.83 a ...
Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran ...
Pent-up demand, improved mortgage deals and people’s desire to find a property ahead of the Autumn Budget have been key motivators for house hunters to finalise their search.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results